Skip Navigation

European Heart Journal 1997 18(1):31-40;
Copyright © 1997 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1997 The European Society of Cardiology

Doppler flow and echocardiography in functional cardiac insufficiency: Assessment of nisoldipine therapy

Results of the DEFIANT-II study

The DEFIANT-II Research Group

Abstract

Aims A multicentre, double-blind, placebo-controlled trial was conducted in 542 patients, randomized 7–10 days after myocardial infarction, to study the effect of nisoldipine coat-core (nisoldipine-CC) on exercise after 6 months. Secondary endpoints included exercise-induced ischaemia, left ventricular function measured by Doppler echocardiography, adverse cardiac events and clinical outcome.

Methods and results Patients had reduced left ventricular ejection fraction between 25 and 50%, but no heart failure. Exercise time was not different in the two groups. Nisoldipine-CC prolonged time to 1 mm ST deviation (P=0·03). There was an effect of nisoldipine-CC of +3·6cm. s–1 on early peak velocity (P=0·01 and of –6·2 ms on isovolumic relaxation time (P=0·005), but no effects on left ventricular volumes or ejection fraction. There was a trend towards reduced mortality (one death in the nisoldipine-CC group vs seven in the placebo group, P≥0·07) and the combined end-point of mortality and cardiac events (P0·09). Peripheral oedema occurred in 49 patients assigned to nisoldipine-CC and two assigned to placebo (P≥0·001). There were no differences in non-cardiac events.

Conclusions Nisoldipine-CC did not improve exercise time but increased time to 1 mm ST deviation, and improved diastolic left ventricular function. It is safe and well tolerated in post-infarction patients with impaired left ventricular function.

Key Words: Calcium antagonist • post-MI • bicycle ergometry • Doppler echocardiography


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer
Drug Therapy for Prevention of Recurrent Myocardial Infarction
Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
J. R. Kizer and S. E. Kimmel
Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards
Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
L. H. Opie
First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents
J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1967 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. R. Abernethy and J. B. Schwartz
Calcium-Antagonist Drugs
N. Engl. J. Med., November 4, 1999; 341(19): 1447 - 1457.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.